Background-Incidence, any trend over time, and predictors of ischemic stroke after an acute myocardial infarction (AMI) in diabetic patients are unknown. Methods and Results-Data for 173 233 unselected patients with an AMI, including 33 503 patients with diabetes mellitus, were taken from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admissions (RIKS-HIA) during 1998 to 2008. Ischemic stroke events were recorded during 1 year of follow-up. Patients with diabetes mellitus more often had a history of cardiovascular disease, received less reperfusion therapy, and were treated with acetylsalicylic acid, P2Y12 inhibitors, and statins to a lesser extent compared with patients without diabetes mellitus. However, the use of evidence-based therapies increased markedly in both groups during the study period. The incidence of ischemic stroke during the first year after AMI decreased from 7.1% to 4.7% in patients with diabetes mellitus and from 4.2% to 3.7% in patients without diabetes mellitus. Risk reduction was significantly larger in the diabetic subgroup. Reperfusion therapy, acetylsalicylic acid, P2Y12 inhibitors, and statins were independently associated with the reduced stroke risk. Conclusions-Ischemic stroke is a fairly common complication after an AMI in patients with diabetes mellitus, but the risk of stroke has decreased during recent years. The increased use of evidence-based therapies contributes importantly to this risk reduction, but there is still room for improvement. (Circ Cardiovasc Qual Outcomes. 2014;7:95-101.)
D iabetes mellitus (DM) is a growing problem in almost all
parts of the world, and recent estimates project a >50% increase in the proportion of people living with DM by 2030. 1 DM is associated with a greater risk of cardiovascular disease, and almost one third of patients with acute myocardial infarction (AMI) may have undiagnosed DM on admission. 2 Several factors affect patients' short-and long-term outcome after AMI, and stroke is one of them. Stroke after AMI is a devastating event with a high mortality rate. [3] [4] [5] [6] The importance of DM as a risk factor for ischemic stroke after AMI is unknown, and potential risk factors for ischemic stroke in patients with diabetes mellitus who suffer an AMI have not been studied. Most published results concerning post-AMI stroke were conducted several years ago, included small patient populations, or had a nonrepresentative patient selection process. Some researchers found that DM was associated with a significantly increased risk of post-AMI stroke, 6 -10 whereas others did not. 4, 5, [11] [12] [13] Acute and secondary preventive treatments for AMI have changed dramatically during the recent decade and may have influenced the risk of post-AMI stroke. In the diabetic AMI population, there are no data about changes in post-AMI stroke risk and no conclusive data published, even in general AMI population, about change in stroke risk during recent years. 5, 11 In the present study, we evaluated DM as a risk factor for ischemic stroke in a nonselected population during the first year after AMI. Previous studies have shown that most post-AMI strokes occur within the first year. 7, 9 We also examined potential risk factors as well as trends over time in the incidence of ischemic stroke in patients with and without diabetes mellitus suffering from an AMI from 1998 to 2008.
Methods
Patient data were obtained from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admissions (RIKS-HIA). This is a national registry in which all patients admitted to a coronary care unit in the participating hospitals are registered. The RIKS-HIA registry, which is now part of the SWEDEHEART registry, has been previously described.
14,15 RIKS-HIA was initiated in 1995 and comprises 19 hospitals, with the coverage increasing to 58 out of 81 hospitals in 1998. This number gradually increased during the study period up to 2008, when 74 out of 74 hospitals with coronary care units were covered by the RIKS-HIA registry, consequently covering >95% of Swedish coronary care unit admissions. 14 In RIKS-HIA, patient data are reported on case record forms that include >100 variables, which are recorded on admission, in hospital, and at discharge. The validity of data entered is examined annually and shows 94% to 97% conformity between RIKS-HIA data and patient records.
The criteria for AMI are standardized and identical for all participating hospitals. From 1998 to 2001, the World Health Organization definition was used. 16 Beginning in late 2001, the criteria of the European Society of Cardiology/American College of Cardiology/ American Heart Association consensus documents were adopted. 17, 18 A total of 173 233 patients, first registered between January 1998 and December 2008, were included.
The RIKS-HIA database became amalgamated with the National Patient Register (NPR) to identify ischemic stroke occurrences <365 days of AMI. NPR includes dates for admission and discharge, as well as diagnoses at discharge for all hospital stays in Sweden. The International Classification of Diseases 9th Revision (433 and 434) and 10th Revision (I63 and I64) codes for cerebral infarction were used. After 2000, the frequency of missing primary diagnoses in NPR has been low, at 0.5% to 0.9% in somatic care. A diagnosis of stroke or transient ischemic attack in NPR has a positive predictive value of 98.6%. The proportion of stroke events identified through NPR ranges from 84.2% to 98% in validation studies. 19 Clinical characteristics and medications on admission and at discharge were extracted from the amalgamated database. A patient was categorized as diabetic if there was a previous diagnosis of DM. In the beginning of the study period, some variables had a significant proportion of missing data. The number of valid cases is presented for these variables to facilitate assessment.
All patients for whom data were entered into RIKS-HIA were informed of their participation in the registry (patients could request to be excluded from the registry) and the long-term follow-up. The registry was approved by the National Board of Health and Welfare and the Swedish Data Inspection Board. The merging of registries was approved by the local ethics committee.
Statistical Analysis
The study period was divided into 4 time periods (January 1998 to Kaplan-Meier curves were calculated for ischemic stroke occurrences during the 4 time periods and were compared between groups using the log-rank test. Uni-and multivariable predictors of risk for ischemic stroke <1 year after admission were assessed using Cox proportional hazards regression analysis. For our multivariable model, we used previously established predictors of risk for ischemic stroke and added all variables from our univariable analyses regardless of statistical significance. In the case of missing data, data were imputed using the technique of multiple imputation. Patients who died during hospitalization were excluded from the analysis when variables regarding treatment at discharge were included. A P value <0.05 was considered significant. Statistical analyses were performed with SPSS 20.0 software and R software, using the packages Hmisc and rms for multiple imputation and estimation of the multivariable model.
Results
From a total of 173 233 patients, 33 503 (19%) had previously diagnosed DM. Baseline patient characteristics are shown in Table 1 . Patients with diabetes were older (74.0 versus 73.0 years), were more often women, had a higher body mass index, and smoked less compared with patients without diabetes mellitus. Patients with diabetes mellitus more often had a history of treated hypertension as well as other cardiovascular diseases. Signs of heart failure during hospitalization were more common in the diabetic group (45.7% versus 32.7%). Patients with diabetes mellitus less often had an ST-elevation myocardial infarction (STEMI) and received less reperfusion therapies.
Characteristics of patients with diabetes mellitus stratified by time period and occurrence of ischemic stroke <1 year post-AMI are shown in Table 2 . The prevalence of hypertension increased during the study period and was consistently higher in patients suffering a stroke, who were also more likely to have other cardiovascular diseases. A previous stroke was considerably more common in the stroke group. Atrial fibrillation and signs of heart failure during hospitalization decreased in both groups but continued to be more common in patients suffering a stroke. There was a marked shift from thrombolysis to percutaneous coronary intervention (PCI) as a reperfusion method. Table I in the Data Supplement shows the corresponding data for patients without diabetes mellitus. Table 3 shows prescription patterns at discharge for patients with diabetes mellitus. The use of acetylsalicylic acid (ASA), P2Y12 inhibitors, β-blockers, calcium antagonists, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and statins increased over time regardless of ischemic stroke, with increases seen particularly for P2Y12 inhibitors and statins. Patients without a stroke post-AMI more often received treatment with ASA, P2Y12 inhibitors, β-blockers, calcium antagonists, angiotensin receptor blockers, and statins, whereas treatment with angiotensin-converting enzyme inhibitors or diuretics was less frequent. The prescribing patterns for patients without diabetes mellitus were similar (Table II in the  Data Supplement) .
In total, 1848 (5.5%) patients with diabetes mellitus experienced an ischemic stroke <1 year after admission for AMI. Ischemic stroke rates decreased substantially from 7. Figure 1A ). All stroke occurrences during the initial hospital stay were coded to have occurred at the beginning of follow-up, hence the Kaplan-Meier curves appear so. There was a significant interaction between DM and time
WhAT IS KnOWn
• Patients with diabetes mellitus have an increased risk of cardiovascular disease.
• A large proportion of patients who suffered a myocardial infarction have diabetes mellitus, diagnosed or undiagnosed.
• Strokes occurring after myocardial infarction carry a high mortality.
WhAT ThE STUDy ADDS
• The incidence of ischemic stroke after myocardial infarction is higher among persons with diabetes mellitus compared with nondiabetic counterparts.
• Among persons with diabetes mellitus, the risk of ischemic stroke <1 year after the first myocardial infarction has markedly decreased between 1998 and 2008. This decrease is larger than in patients without diabetes mellitus.
• The increased use of evidence-based therapies contributes to the larger risk reduction seen in patients with diabetes mellitus.
period (early versus late) regarding the risk of ischemic stroke (P<0.01), with a significantly larger risk reduction in patients with diabetes mellitus. The interaction is illustrated in more detail in Figure 2 . For patients without diabetes mellitus, ischemic stroke rate decreased from 4.2% to 3.7% ( Figure 1B) . The univariable Cox regression analysis for patients with diabetes mellitus is shown in Table 4 .
In the multivariable Cox regression analyses (Table 5) , age, previous ischemic stroke, STEMI, and atrial fibrillation during hospitalization were independently associated with an increased stroke risk, whereas PCI during hospitalization and treatment with ASA, P2Y12 inhibitors, and statins at discharge were independently associated with a decreased risk of stroke.
The univariable and multivariable Cox regression analyses for patients without diabetes mellitus are shown in Tables III  and IV 
Discussion
The present study has a size and duration that make it possible, for the first time, to reliably assess the incidence, risk factors, and time trend for post-AMI ischemic stroke in patients with diabetes mellitus. Stroke incidence during the first year post-AMI decreased during the study period from 4.2% to 3.7% and from 7.1% to 4.7% in patients without and with diabetes mellitus, respectively, showing that this serious complication is not a rare event. These incidence rates are higher than those previously reported and underscore the importance of nonselected patient populations when assessing complication rates after AMI. Clinical trials typically report post-AMI stroke rates of 2.3% to 2.8% during the first year probably because of the exclusion criteria used. 9, 10 A 19% prevalence of previous DM was found, a slightly lower figure when compared with other studies. 5, 9, 12 The prevalence would have been higher if data for fasting glucose or HbA1c had been available to define DM. 2 DM has been associated with post-AMI stroke in some studies [6] [7] [8] [9] [10] but not in others. 4, 5, [11] [12] [13] The major reasons for contradictory results are probably inadequate study sizes, exclusion of high-risk patients, and short follow-up durations.
Predictors
Consistent with previous studies, older age, previous stroke, STEMI, atrial fibrillation, and heart failure predicted ischemic stroke in the multivariable model. 4, [6] [7] [8] [9] 11, 12, 20 PCI during hospitalization, as well as treatment at discharge with ASA, P2Y12 inhibitors, or statins, predicted a decreased risk of ischemic stroke in patients with and without diabetes mellitus.
The preventive effect seen with PCI could depend on a reduced myocardial ischemic injury with a decreased inflammatory reaction resulting in reduced platelet reactivity. 21 ASA is a standard therapy in secondary prevention after AMI and effectively reduces the risk of stroke. 22 ASA has also been associated with a reduced risk of undefined strokes in a registry study. 4 The present results confirm the preventive effect of ASA in a large, nonselected cohort of patients with AMI in terms of ischemic stroke.
P2Y12 inhibitors, mainly represented by clopidogrel, also proved to be predictors of reduced risk. Several studies have shown a decrease in major adverse events with P2Y12 inhibitors. [23] [24] [25] The Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY), Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE), and Clopidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT) studies showed an insignificant decrease in the rate of undefined strokes. [23] [24] [25] These studies, however, are exposed to several weaknesses, including patient selection in CLARITY, low proportion of AF indicates atrial fibrillation; BMI, body mass index; CABG, coronary artery bypass grafting; HF, heart failure; LDL, low-density lipoprotein; MI, myocardial infarction; n, number of valid cases; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; and STEMI, ST-elevation myocardial infarction.
verified AMI in CURE, and absence of a loading dose of clopidogrel in COMMIT, making them less applicable.
The present results show that statin treatment is associated with a reduced risk of ischemic stroke in unselected patients with AMI. A stroke preventive effect has been shown previously in more selected patient populations in randomized trials, including high-risk patients and patients with acute coronary syndrome. 26, 27 The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study, assessing atorvastatin 80 mg in patients with acute coronary syndrome patients, found a borderline significant decrease in stroke, a secondary outcome, in statin-treated patients. 27 The stroke preventive effect of statins is further supported by the results of a meta-analysis showing a significant stroke reduction in both primary and secondary prevention. 28 
Time Trends
The decrease in ischemic stroke rate <1 year post-AMI in patients without and with diabetes mellitus over the entire study period may be explained in part by the decreased occurrence of established risk factors for stroke (STEMI, atrial fibrillation, and heart failure). The increased use of protective therapies (PCI, ASA, P2Y12 inhibitors, statins) probably is also an important contribution to the declining stroke rate.
The larger decrease in risk of post-AMI stroke seen in the diabetic population may indicate that patients with diabetes mellitus have gained more from the increased use of evidencebased therapies in terms of reduced ischemic stroke, thus explaining the interaction found between time period and DM in the present study. There are convincing data published supporting a greater preventive effect of evidence-based therapies in patients with diabetes mellitus.
29,30

Mechanisms
The precise mechanisms behind the increased risk of stroke after AMI are not known. One common theory is that left ventricular thrombus releases arterial emboli. The formation of a ventricular thrombus occurs almost exclusively after an anterior STEMI. However, only about one third of the present patients suffering a stroke had STEMI, and a large proportion of these were nonanterior, invalidating the left ventricular thrombus theory. Furthermore, patients with diabetes mellitus had a higher risk of stroke but a lower proportion of STEMI. Moreover, anticoagulants during the initial period after AMI, which definitely decreases the incidence of left ventricular thrombus, have not been shown to decrease the incidence of ischemic stroke, 9, 13, [31] [32] [33] and there was no association with reduced stroke risk in the present study. Instead, we think that an important mechanism behind ischemic stroke during the early post-AMI period could be increased inflammation and platelet reactivity. This could explain the increased risk of stroke in patients with diabetes mellitus as well as the preventive effect of antiplatelet and statin treatment.
21
Implications
Although the decrease in ischemic stroke rate was larger in patients with diabetes mellitus, they still had a higher risk of stroke at the end of the study period as compared with patients without diabetes mellitus. Previous data have shown an underutilization of evidence-based treatments, which is consistent with the present results. [34] [35] [36] [37] [38] Consequently, there is room for an increased use of evidence-based therapies to prevent ischemic stroke and other vascular complications post-AMI, and patients with diabetes mellitus would gain the most. 29 The use of more potent P2Y12 inhibitors would probably also result in a greater clinical benefit in patients with DM.
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Limitations
A limitation of this study is that some of the variables in the analysis had a low number of valid cases. In general, the distribution of missing data was balanced between patients without and with diabetes mellitus, men and women, and age groups. Most of the missing data are because of the earlier time periods when some of the variables were yet to be included in the database. This was especially true in the early time periods for heart rate, blood pressure, P-glucose, and angiotensin receptor blocker, and through the entire period for body mass index, P-cholesterol, and P-low-density lipoprotein. Also, when trying to establish independent risk factors with a Cox multivariate model, there is always the risk of confounders that are not taken into account because they were not recorded as variables in the database. Furthermore, the analysis of interaction between DM and time period (early versus late) regarding the risk of ischemic stroke was not prespecified.
Conclusions
Ischemic stroke is a fairly common complication <1 year after AMI in patients with diabetes mellitus, but the risk of stroke decreased from 1998 to 2008. An increased use of PCI, ASA, statins, and P2Y12 inhibitors contributed importantly to the reduced stroke risk.
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